Lahbabi 2013.

Methods	Randomised trial Dates the study was conducted: from June 2009 to August 2011 Funding sources and potential conflicts of interest: No information reported on funding Authors declare no conflicts of interest Definition of compliance: evaluated by pill count. Compliance was considered good if ≥ 90% and poor if ≤ 60%
Participants	Number and type of participants: 327 H.pylori‐positive participants were enrolled in the study Participants were randomised to 3 different treatment groups: 2 groups with 7‐day standard triple regimens (different antibiotic amoxicillin versus metronidazole) and 1 group with10‐day sequential regimen. According to our study question, only the data referring to the 7‐day STT (amoxicillin group) and the 10‐day SEQ are relevant Country: Morocco Number of participants randomised: 323 (ITT sample) Number of participants in the 7‐day STT arm: 115 Number of participants in the 10‐day SEQ arm: 104 Mean age (SD) of the population reported by treatment group, 7‐day STT: 48.5 (14.8) 10‐day SEQ: 47.5 (15) Total of participants: 47 (14) Sex ratio (M / F) by treatment group 7‐day STT: 0.83 10‐day SEQ: 1.19 Number (%) of PUD participants at baseline, by treatment group: 7‐day STT: 30/115 (26) 10‐day SEQ: 21/104 (20) Number (%) of participants with gastric ulcer, by treatment group: 7‐day STT: 4/115 (3.4) 10‐day SEQ: 2/104 (2) Number (%) of participants with NUD, by treatment group: 7‐day STT:85/115 (74) 10‐day SEQ: 83/104 (80) H. pylori diagnostic methods in all treatment arms: H. pylori infection was determined by at least 1 of the following tests: histology and/or PCR
Interventions	Name, dose timing of antibiotics in 7‐day STT: omeprazole 20 mg twice a day + clarithromycin 500 mg twice a day + amoxicillin 1 g twice a day Name, dose timing of antibiotics in 10‐day SEQ: omeprazole 20 mg twice a day + amoxicillin 1 g twice a day (during 5 days) and omeprazole 20 mg twice a day + clarithromycin 500 mg twice a day + metronidazole 500 mg twice a day (during 5 days) Sensitivity test (yes/no) to antibiotics before/after treatment: not performed Method of assessment of H. pylori status after treatment: ¹³C‐urea breath test Time for assessment of H. pylori status after treatment: 3 months
Outcomes	ITT eradication rate (%) by treatment group: 7‐day STT: 90/115 (78.2) 10‐day SEQ: 98/104 (94.2) PP eradication rate (%) by treatment group: 7‐day STT: 90/113 (79.6) 10‐day SEQ: 98/102 (96.1) Adherence rate (%) as > 90% to therapy by treatment group: 7‐day STT: 106/115 (92.2) 10‐day SEQ: 98/104 (94.2) Metronidazole resistance (%) before treatment, SEQ ITT/PP: not reported Metronidazole resistance (%) before treatment, STT ITT/PP: not reported Clarithromycin resistance (%) before treatment, SEQ ITT/PP: not reported Clarithromycin resistance (%) before treatment, STT ITT/PP: not reported Incidence (%) rate of (total) AEs by treatment group: 7‐day STT: 32/115 (827.8) 10‐day SEQ: 10/104 (9.6) Incidence (%) serious AEs SEQ/STT: not reported
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomisation was made by a computer‐generated list drawn up by a statistician
Allocation concealment (selection bias)	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	Low risk	Primary outcome data were clearly reported
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Single‐blinded
Publication format	Low risk	Full article